Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Nat Med. 2010 Feb;16(2):232-6. doi: 10.1038/nm.2080. Epub 2010 Jan 17.
Delayed myeloid engraftment after cord blood transplantation (CBT) is thought to result from inadequate numbers of progenitor cells in the graft and is associated with increased early transplant-related morbidity and mortality. New culture strategies that increase the number of cord blood progenitors capable of rapid myeloid engraftment after CBT would allow more widespread use of this stem cell source for transplantation. Here we report the development of a clinically relevant Notch-mediated ex vivo expansion system for human CD34(+) cord blood progenitors that results in a marked increase in the absolute number of stem/progenitor cells, including those capable of enhanced repopulation in the marrow of immunodeficient nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice. Furthermore, when cord blood progenitors expanded ex vivo in the presence of Notch ligand were infused in a clinical setting after a myeloablative preparative regimen for stem cell transplantation, the time to neutrophil recovery was substantially shortened. To our knowledge, this is the first instance of rapid engraftment derived from ex vivo expanded stem/progenitor cells in humans.
脐血移植(CBT)后骨髓造血延迟被认为是移植物中祖细胞数量不足所致,与早期移植相关发病率和死亡率增加有关。新的培养策略可增加 CBT 后能够快速骨髓造血的脐血祖细胞数量,从而使这种干细胞来源更广泛地用于移植。在此,我们报告了一种临床上相关的 Notch 介导的人 CD34(+)脐血祖细胞体外扩增系统的开发,该系统可显著增加干细胞/祖细胞的绝对数量,包括那些在免疫缺陷非肥胖糖尿病-严重联合免疫缺陷(NOD-SCID)小鼠骨髓中能够增强重建造血的细胞。此外,当在存在 Notch 配体的情况下对脐血祖细胞进行体外扩增,并在接受清髓性预处理方案进行干细胞移植后输注到临床环境中时,中性粒细胞恢复的时间大大缩短。据我们所知,这是首例源自人类体外扩增的干细胞/祖细胞的快速植入。